Overview
MedPharm is a contract development and manufacturing organization focused on topical, transdermal, and mucosal drug delivery. It provides end-to-end services from formulation development through clinical and commercial manufacturing, including analytical testing and regulatory support, and operates proprietary delivery platforms such as MedSpray, MedTherm, and AquaRMed to enable multiple administration routes. The company combines contract research with a patent portfolio and offers lifecycle support across development and manufacturing, differentiating itself from competitors. A July 2024 merger with Tergus Pharma expanded capabilities to include hormone-based and highly potent drugs, enhancing scale and scope with the aim of helping pharma and biotech move products from early formulation to scalable manufacturing.
Work here?Claim your company
Simplify's take
What believers are saying
- February 2025 CEO Bill Humphries signals post-merger growth execution and commercial discipline.
- The Durham $4 million expansion created space for over 100 skilled hires in RTP.
- Palvella's positive March 2026 Phase 3 readout and Purna partnership strengthen sponsor validation.
What critics are saying
- MedPharm depends on niche topical spending; a sponsor slowdown hits utilization fast in 2025-2026.
- The 2024 merger left some Tergus leaders exiting, creating integration and execution risk.
- Topical CDMO giants and captive pharma plants can compress margins and steal repeat programs.
What makes MedPharm unique
- MedPharm remains the topical and transepithelial CDMO specialist after the 2024 Tergus merger.
- Durham and Guildford sites give MedPharm integrated development, clinical manufacturing, and commercial production.
- August 2026 Olink CSP status adds proprietary proteomics beyond formulation and in vitro testing.
Help us improve and share your feedback! Did you find this helpful?